PubMed Health⌕ Search

Biomedical subjects

F Dray

Publications and source records attributed to F Dray.

At least 163 records · Page 9Linked to original sources
PubMed1975

Radioimmunoassay of prostaglandins Falpha, E1 and E2 in human plasma.

Antibodies against prostaglandins (PG)F2alpha, E1 and E2 were obtained inrabbits immunized with respectively PG F2alpha, PG E1 and PG E2 conjugated to bovine serum albumin by carbodiimide. A radioimmunoassay capable of measuring 7 pg of PG Falpha, 2 pg of PG E2 and 14 pg of PG E1 in human peripheral plasma is described. Plasma samples (pH 3, citric acid) are extracted with cyclohexane: ethyl acetate, 1:1 and then chromatographed on silicic acid columns to separate the prostaglandins into three fractions: fraction I, PG A, PG B and some unknown immunoreactive compounds; fraction II, PG E and fraction III, PG Falpha. The recovery is 80+ +/- 6.2. Mean plasma levels in adults of PG Falpha and PG E, expressed in pg/ml: -PG Falpha 12 +/- 2.8 (n- 25 men), 8 +/- 2.3 (n= 18 women, follicular phase), 7 +/- 1.4 (n= 18 women, luteal phase). -PG E1 40.5 +/- 7.6 (n= 13 men), 38 +/- 17.1 (n= 10 women). -PG E2 4.5 +/- 1 (n= 12 adult subjects). The major characteristics of the method described herein are the following: - a large volume of plasma has to be processed (10 ml or more for PG Falpha and PG E1, 5 ml or more ofr PG E2). - a chromatographic step is necessary to separate the different prostaglandins which makes it possible to circumvent probelms of immunological cross reactivity and interference with unknown immunoreactive compounds. - great care has been taken in collection of blood samples, especially to insure complete removal of blood cells namely platelets.

Bloodletting↗
PubMed1975

The biological effects of injected antibodies to estradiol-17 beta and to progesterone in pregnant rats.

Estradiol-17 beta (E2) and progesterone (P) levels have been effectively reduced in pregnant rats by injecting them with antibodies which bind E2 or P (A-E2- or A-P) with high specificity. Before, and at daily intervals after treatment with A-E2 or A-P, blood was collected sequentially from the tail vein and the levels of circulating A-E2, A-P total E2 (E2t) and total P (Pt) determined. Having established the relationship between A-E2, E2t, bound E2 (E2b) and unbound E2 (E2u), as well as between A-P, Pt, bound P (Pb) and unbound P (Pu), the concentrations of E2u and Pu could be calculated reliably. Treatment of gestating rats with A-E2 and A-P lowered E2u and Pu levels significantly (P less than 0.001). In comparison with the 14 controls, the 17 A-E2 treated (and thus E2u-deficient) animals showed significant increases in placental weight (P less than 0.001). This effect of A-E2 was readily prevented by replacement therapy with diethylstilbestrol (DES), since A-E2 does not bind DES. In 21 pregnant rats, treatment at day 10 of gestation with only 2 ml A-P (total "Binding Capacity" = 6 mug P) critically lowered the Pu levels and provoked abortion. In contrast, the same treatment in 12 rats at day 6 of gestation (when the P levels are higher than at day 10) failed to provoke the appropriate degree of P-withdrawal (Pw) and abortion, illustrating the quantitative nature of the relationship between effective A-P treatment, Pw and the termination of pregnancy.

Animals↗